I agree with that.
Where we don't agree is the intrinsic value based on some now apparent impactful events happening over the coming months.
IMO, soon to be reflected in the market value.
Let's say Regen receives an Orphan designation on Hema (highly probable) and files their NR2F6 IND...per external estimates the market cap in many cases for small molecule INDs increases company cap to hundreds of millions ( Lander said $500mm). Let's use $250mm.
In a vacuum, 23% of the common puts BMSN back over a penny based on 5b shares. If lander is right, over 2.2 pennies.
Keep in mind the small molecule IND is projected to be filed in Q2.
Not to mention the other items..Hema, Orphan, DcellVax NIH, etc.
My opinions based on factual research. Will it happen...time will tell. Will BMSN ever reach what the price should be based on its percentage ownership of Regen....time will tell.
I am hopeful, and positioned accordingly.
BMSN
